Articles tagged with Molecular Imaging
Researchers have developed a new theranostic approach using copper radionuclides that improves survival rates and reduces tumor volume in neuroendocrine tumors. The new method produces high-quality PET images and demonstrates improved efficacy when delivered as two fractionated doses.
The Journal of Nuclear Medicine has published a special supplement commemorating six decades of leadership in the field, featuring influential manuscripts that shaped the future of medicine. The supplement highlights landmark papers on PET, Anger camera, and fusion PET/CT, as well as the journal's past editors and associate editors.
A proof-of-concept study found that 68Ga-pentixafor PET imaging effectively diagnoses and manages rare CNS B-cell lymphoma by targeting the CXCR4 biomarker. The imaging modality showed excellent contrast characteristics between lymphoma lesions and surrounding healthy brain tissue.
This article discusses the integration of ultrasound imaging in medicine and biology, enabling advanced techniques such as molecular imaging and therapy. The use of ultrasound contrast agents and microbubble cavitation has opened up new opportunities for intracellular delivery and cancer treatment.
A single-center observational study found that PET/MRI improves lesion detectability in select cancers and significantly reduces overall radiation exposure compared to PET/CT. The study, published in The Journal of Nuclear Medicine, shows that PET/MRI can promote fast, efficient local and whole-body staging in one step.
The SNMMI Wagner-Torizuka Fellowship provides extensive training and experience for Japanese physicians in nuclear medicine and molecular imaging. The program has graduated 30 fellows since its inception and supports the worldwide advancement of nuclear medicine and molecular imaging.
Researchers have developed a new imaging technique called single-molecule orientation localization microscopy (SMOLM) that allows them to distinguish between different phases of lipid molecules in cell membranes. This technique uses fluorescent probes to directly 'see' the probe's orientation and determine its chemical composition.
Researchers developed a simplified process to estimate radiation dose using a single post-treatment SPECT/CT scan, potentially improving therapeutic outcomes by tailoring treatments to individual patients' physiology. The method was applied to 177Lu-PSMA-617 therapy for metastatic prostate cancer.
A simple, low-cost device tests mask effectiveness in blocking droplet emissions during normal wear. The study found that N95 masks without valves and surgical/polypropylene masks perform well, while hand-made cotton face coverings provide good coverage, but bandanas and neck fleeces offer little protection.
A new alpha-radioimmunotherapy has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice. The therapy targets CD38 protein on tumoral cells and reduces unwanted radiation exposure on normal tissues.
Research at SNMMI 2020 Annual Meeting found super-agers have lower tau and amyloid pathology associated with neurodegeneration. This enables them to maintain their cognitive skills even at advanced ages. The study suggests a potential pathway for successful aging and developing novel treatments to tackle age-related diseases.
Researchers used a novel imaging agent to visualize inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction. The study found a systemic inflammatory response, suggesting a potential mechanism for disease progression and therapy response.
Stephen L. Bacharach, PhD, is recognized for his contributions to gated cardiac blood pool imaging, informatics, and data processing. His research has had a significant impact on nuclear medicine and cardiology.
A new molecular imaging approach using PET/MRI has been developed to precisely identify the location of pain generators in chronic pain patients. This approach resulted in a significant modification of management plans for nearly half of the patients, with some receiving invasive procedures.
A novel bone imaging approach has established that bone metabolism is abnormally elevated in patients with knee osteoarthritis. This finding provides a new functional measure to assess degeneration of the knee joint, and may help develop interventions to slow or arrest its progression.
Peter S. Conti, MD, PhD, received the 2020 Benedict Cassen Prize for his pioneering work in radiopharmaceuticals and clinical PET applications for cancer imaging. The award recognizes his contributions to advancing nuclear medicine and molecular imaging.
A new radiotracer measures synaptic density changes in the brain after stroke, providing an objective and quantitative measure of disease progression. This method may also help detect stroke early and evaluate recovery.
A new PET radiotracer has been proven safe and effective in imaging malignant brain tumors with high sensitivity. The radiotracer targets αvβ3 integrin, which is overexpressed in glioblastomas, allowing for superior visualization of tumors.
Researchers developed a novel radioiodinated PSMA-targeting radiopharmaceutical that can be produced in high yields without generating volatile byproducts. The agent shows exceptional effectiveness for precision diagnosis and treatment of prostate cancer in preclinical studies, targeting prostate-specific membrane antigen (PSMA).
A multicenter trial found that PSMA PET/CT identified disease in over half of patients with negative conventional imaging, leading to changes in management in 66% of cases. The most common changes were conversion to surgery or radiation, or addition of nodal-directed therapy.
A new study using uEXPLORER technology successfully detected metastatic cancer in patients, providing high-quality images of tumor behavior. Parametric images showed improved visibility of cancer lesions detection and multi-parametric characterization of tumor metastases.
Carolyn J. Anderson, PhD, has been recognized for her pioneering work in radiometal-based radiopharmaceuticals for diagnostic imaging and targeted radiotherapy of cancer and other diseases. Her research focuses on developing imaging agents for upregulated receptors on immune cells involved in inflammation related to lung diseases.
Targeted radionuclide therapy has been shown to improve the effectiveness of immunotherapies in treating prostate cancer by modifying the tumor microenvironment. The treatment can achieve immunomodulation at relatively low radiation doses without affecting the normal immune system.
The uEXPLORER TB-PET/CT scanner offers a new imaging option for inflammatory arthritis by capturing glucose metabolism in normal and diseased joint tissues across the body. This allows for quantifying systemic inflammatory burden, which could have direct implications for disease staging, treatment selection, and monitoring of treatment...
Researchers developed a microscope to monitor wound healing without harming the subject. They studied mice with untreated wounds, placebo treatments, and different concentrations of treatment drugs to understand how topical drugs affect the skin.
The COVID-19 pandemic has accelerated the adoption of telemedicine in nuclear cardiology, enabling continued service during outbreaks. Nuclear medicine also offers potential for repurposing pharmaceuticals and developing new treatments targeting different aspects of the virus.
Researchers used molecular imaging to track DNA damage in neuroendocrine tumors treated with 177Lu-DOTATATE. The technique enabled visualization of γH2AX foci just days after treatment, providing insights into therapeutic outcomes and potential dose adjustments.
Researchers have found that the new radiotracer 18F-PSMA-1007 offers advantages over established agent 68Ga-PSMA-11 in staging prostate cancer. The study showed near-equal performance between the two tracers, with 18F-PSMA-1007 detecting additional lesions in four patients.
Patients receiving 177Lu-DOTATATE radiation therapy may experience travel delays at U.S. ports of entry due to residual radiation activity; carrying a travel card with treatment information can help alleviate this issue.
The global nuclear medicine community has shared approaches to containing the spread of COVID-19, including triage, reduced elective studies, improved hygiene practices, and rotation of medical personnel. These measures aim to minimize patient contact and optimize distance to reduce the risk of transmission.
Researchers used total-body PET imaging to track the distribution of 89Zr-labeled antibodies in preclinical trials, achieving excellent image quality up to 30 days after injection. The study demonstrates the potential of this technique for extended imaging windows and low-dose radioactivity.
Researchers developed a fluorescence-based technique to monitor single molecules, accelerating structural biology and potentially aiding in structure-guided drug design. The technique uses FRET to visualize biomolecules with unprecedented spatial and temporal resolution.
Researchers used PET myocardial perfusion imaging to quantify myocardial blood flow and flow reserve, successfully detecting cardiac allograft vasculopathy and predicting prognosis. The study found MFR had higher accuracy in predicting overall prognosis for cardiac transplant patients.
Researchers have identified several potentially useful breast cancer biomarkers that indicate the presence and risk of malignancy. PET/MRI imaging revealed differences in biomarkers between healthy contralateral breast tissue of patients with malignant and benign breast tumors.
Researchers at Helmholtz Munich have created a technique called Mid-infraRed Optoacoustic Microscopy (MiROM) that provides real-time images of biomolecules in living cells without the need for labels or contrast agents. This method offers novel insights into metabolic processes and can be used to study the effects of different diets on...
Researchers developed a novel noninvasive imaging technique using multispectral optoacoustic tomography (MSOT) and ultrasound to diagnose thyroid disorders. MSOT/ultrasound images revealed significant biomarker changes in Graves' disease and malignant thyroid nodules, showing promise for improved diagnostics.
A new study finds that 68Ga-DOTATATE PET/CT is a more accurate method for selecting patients with neuroendocrine tumors who may benefit from peptide receptor radionuclide therapy. The imaging modality yields significantly higher Krenning scores and detects eligible patients with smaller lesions.
A new dual imaging approach combines transrectal ultrasound (TRUS) and photoacoustic imaging to detect anatomical features and molecular information of the prostate. This technology has shown promise in detecting prostate cancers with high accuracy, including distinguishing malignant regions in patients with advanced disease.
The Journal of Nuclear Medicine has seen a significant increase in its impact factor, with a jump of 25% compared to the previous year. The journal's immediacy index also increased, indicating a faster pace of citation activity.
Researchers found PRRT to be safe and effective for patients with grade 3 neuroendocrine neoplasms, with a median progression-free survival rate of 9.6 months and overall survival rate of 19.9 months. Patients with low Ki-67 index responded more favorably to PRRT.
A novel combination therapy using two targeted treatments has shown to maximize efficacy while reducing side effects in men with progressive prostate cancer. The study found that nearly 70 percent of patients saw a more than 50 percent reduction in PSA levels after the treatment.
Researchers have developed ultrasmall nanoclusters with antioxidative properties that can pass through the kidneys' filtration barrier to alleviate clinical symptoms of AKI. Selenium-doped carbon quantum dots also demonstrated effective treatment and prevention of AKI in mice by localizing in the kidneys and eliminating ROS.
A novel radiotracer has been identified that can detect nearly 30 types of cancer using positron emission tomography/computed tomography (PET/CT). This technology shows promise for new applications in noninvasive diagnosis, staging and treatment.
Research presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting found that tobacco smokers have reduced neuroimmune function compared to nonsmokers. This impairment may contribute to compulsive drug use and cognitive dysfunction in smokers trying to quit.
The Society of Nuclear Medicine and Molecular Imaging announced 13 new SNMMI Fellows, recognizing their outstanding contributions to the field. The recipients include past SNMMI presidents and experts in various areas of nuclear medicine and molecular imaging.
Researchers used PET/CT to evaluate coronary microvascular function in OSA patients and found a link between severe sleep apnea and impaired coronary flow reserve. The study suggests that patients with severe OSA should receive PET myocardial perfusion imaging to exclude coronary microcirculatory dysfunction.
Research shows that adding an interim scan during therapy can help guide patient treatment, predicting survival and tumor response. Interim scans using PSMA PET imaging have shown significant predictive value for overall survival in patients undergoing 177Lu-PSMA radioligand therapy.
Researchers developed a wearable vest to collect data for personalized therapy in patients with metastatic NETs. The device provides organ-specific measurement recordings within the patient's comfort, allowing for more effective treatment and improved progression-free survival.
A study using PET imaging reveals that women with the ApoE 4 allele are more susceptible than men to tau accumulation in the brain. The study also found that sex modulates the effect of ApoE ε4 on brain tau depositing in individuals with mild cognitive impairment.
A new class of radiopharmaceuticals, named radiohybrids (rh), has been developed for cancer imaging and radioligand therapy (theranostics). These rhPSMA-ligands have a unique feature that both fluorine and the metal are always present, but only one of them is present as a radioactive isotope.
A study found that PET/CT imaging can identify diseased areas in patients with extra-pulmonary tuberculosis, guiding personalized therapy. The test provides a whole-body survey, helping to estimate disease extent and predict treatment response.
Di Carli is recognized as an outstanding clinician-scientist, teacher, and mentor, known for pioneering work in cardiovascular radionuclide imaging and services. His research has contributed to understanding ischemic cardiac dysfunction and using positron emission tomography (PET) for guiding management of patients with end-stage heart...
A first-in-human Phase 1/Phase II study demonstrates the safety and efficacy of intravenous administration of technetium-99m tilmanocept for monitoring rheumatoid arthritis disease activity. The imaging agent binds to activated macrophages, providing joint-specific information on RA disease involvement.
Jason S. Lewis, PhD, has received the 2019 Paul C. Aebersold Award from the Society of Nuclear Medicine and Molecular Imaging (SNMMI) for his outstanding contributions to basic nuclear medicine science. His research focuses on developing radiopharmaceuticals for targeted diagnosis and treatment of cancer.
Researchers developed a new type of nuclear medicine scan that quickly and precisely diagnoses inflammation in IBD using monoclonal antibodies directed against specific innate immune cell markers. The immuno-PET scan has high potential for theranostic diagnosis and precision treatment of IBD and other inflammatory diseases.
A multicenter study found that deep learning analysis of single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) improved the diagnosis of obstructive coronary artery disease. The new method showed increased sensitivity and accuracy compared to traditional methods, leading to better patient outcomes.
A 12-year retrospective clinical study shows the long-term effectiveness of PRRT, allowing patients to maintain a high quality of life. The overall response rate is about 70-80 percent, and prognosis is generally favorable for patients who respond to therapy.
The first total-body PET/CT scanner has shown promising results in enhancing image quality, reducing scan time, and lowering dose. Clinical trials have demonstrated improved diagnostic capabilities with minimal impact on patient exposure.
Researchers have identified two new nuclear medicine tracers that provide high-contrast images for cancer diagnosis, allowing for shorter imaging times and no diet changes. The tracers target cancer-associated fibroblasts, promoting tumor growth, migration, and progression.
Researchers have developed a novel PET/CT tracer that detects and characterizes blood clots in the legs, where conventional imaging has limitations. The new imaging agent may provide more accurate diagnoses and information on clot growth or embolization, leading to changes in clinical intervention.